Overview

Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome

Status:
COMPLETED
Trial end date:
2025-01-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
Phase:
PHASE1
Details
Lead Sponsor:
Imbrium Therapeutics
Collaborator:
Purdue Pharma LP